Roche has started a Phase III clinical trial to assess its Actemra/RoActemra in combination with Gilead Sciences’ remdesivir to treat hospitalised Covid-19 patients with severe pneumonia.
Named REMDACTA, the randomised, double-blind, multi-centre trial will compare the safety and efficacy of the combination to remdesivir plus placebo.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Expected to commence patient enrolment next month, the study is designed to involve about 450 patients worldwide, including in the US, Europe and Canada.
